Skip to content

Addiction: all studies

Page 96 of 855: studies 951 to 960 of 8,547, newest first. Back to the addiction overview

Research

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Pharmacology & Therapeutics May 1, 2019 Matthew W Johnson, Peter S. Hendricks, Frederick S. Barrett et al. 520 citations

The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic hallucinogens), which are serotonin 2A receptor (5-HT2AR) agonists such as lysergic acid diethylamide (LSD), mescaline, and psilocybin. Classic psychedelics have been administered as sacraments since ancient times. They were of prominent interest...

The Past and Future of Psychedelic Science: An Introduction to This Issue

Journal of Psychoactive Drugs March 15, 2019 Lisa Jerome, Brad Burge, Richard Doblin et al. 87 citations

Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of...

The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis

International Journal of Drug Policy February 10, 2019 Elena Argento, Kenneth W. Tupper, M. Eugenia Socias 17 citations

The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmacotherapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for innovative interventions...

DOI: 10.1016/j.drugpo.2018.11.006 (opens in new tab) Opioid use disorder Fentanyl Psychological intervention Pharmacotherapy +3

Transformative Psychopharmacology: the Case of 5-Methoxy-N,N-Dimethyltryptamine

International Journal of Psychotherapy Practice and Research January 2, 2019 Jan M. Keppel Hesselink, Jan M. Keppel Hesselink

Since the 2nd part of last century neo-shamanic rituals using mind-altering extracts from plants or animals have become increasingly popular in Europe and the USA. The first rituals coming to the west were based on drinking a special Amazonian tea, Ayahuasca, based on 2 different plants, with active compounds belonging to the class of the beta-carbolines (harmala alkaloids) and tryptamines. The...

Advances in Psychedelic Medicine

2019 17 citations

Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems. More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now...

[Neurotrophic mechanisms of psychedelic therapy].

Biologie aujourd'hui 2019 Rémi Corne, Raymond Mongeau 7 citations

Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and behavioral effects they induce are quite dramatic, they possess little addictive potential when compared to nicotine, alcohol or opiates. Since the discovery of ketamine antidepressant effects, there has been growing interest for these molecules....

Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.

Neuropharmacology November 2018 David J Heal, Jane Gosden, Sharon L. Smith

Psychedelics comprise drugs come from various pharmacological classes including 5-HT2A agonists, indirect 5-HT agonists, e.g., MDMA, NMDA antagonists and κ-opioid receptor agonists. There is resurgence in developing psychedelics to treat psychiatric disorders with high unmet clinical need. Many, but not all, psychedelics are schedule 1 controlled drugs (CDs), i.e., no approved medical use. For...

A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

Neuropharmacology November 1, 2018 Elias Dakwar, Edward V. Nunes, Carl L. Hart et al. 83 citations

Efforts to translate sub-anesthetic ketamine infusions into widespread clinical use have centered around developing medications with comparable neurobiological activity, but with attenuated psychoactive effects so as to minimize the risk of behavioral toxicity and abuse liability. Converging lines of research, however, suggest that some of the psychoactive effects of sub-anesthetic ketamine may...

The neuropsychopharmacology of cannabis: A review of human imaging studies

Pharmacology & Therapeutics October 20, 2018 Michael Bloomfield, Chandni Hindocha, Sebastian F Green et al. 236 citations

receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of...

Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.

Molecules October 11, 2018 Bronwyn M Kivell, Kelly F Paton, Nitin Kumar et al. 45 citations

The acute activation of kappa opioid receptors (KOPr) produces antinociceptive and anti-cocaine effects, however, their side-effects have limited further clinical development. Mesyl Sal B is a potent and selective KOPr analogue of Salvinorin A (Sal A), a psychoactive natural product isolated from the plant Salvia divinorum. We assessed the antinociceptive, anti-cocaine, and side-effects of...